OpenAI Researcher’s AI Drug Discovery Startup Nears $2B Valuation Amid Investor Surge

OpenAI researcher Miles Wang is reportedly in talks to launch an AI drug discovery startup, seeking to raise around $200 million at a $2 billion valuation.

VentureGrill Desk
Updated Nov 8, 2026 2 min read
OpenAI Researcher’s AI Drug Discovery Startup Nears $2B Valuation Amid Investor Surge

OpenAI researcher Miles Wang is preparing to leave the ChatGPT maker to launch a new startup focused on developing artificial intelligence models for drug discovery, according to reporting from TechCrunch citing four people familiar with his plans. Several other researchers from OpenAI are anticipated to join the new enterprise. Wang has been involved in research evaluating how AI systems can automate and accelerate scientific discovery during his time at OpenAI, which he joined in 2024 after leaving Harvard.

According to two sources cited by TechCrunch, the startup is currently in discussions to raise roughly $200 million. The talks peg the pre-money or initial valuation of the fledgling company at $2 billion. Venture capital firm Lightspeed is reportedly in discussions to lead the financing round. Sources cautioned that these talks remain ongoing, the deal is not yet finalized, and specific terms could still change.

When contacted by TechCrunch, Wang disputed the report's funding figures and the description of the company, though he did not provide alternative numbers or specific corrections. Lightspeed declined to provide a comment to the publication regarding the potential investment negotiations.

The fundraising discussions highlight robust investor appetite for applying artificial intelligence to achieve breakthroughs within the life sciences sector. This market enthusiasm is underscored by other recent mega-rounds in the space. Chai Discovery, a two-year-old startup building AI models to predict molecular interactions for drug identification, recently announced a $400 million funding round at a $3.8 billion valuation, co-founded by former OpenAI researcher Josh Meier. Additionally, Google DeepMind spinout Isomorphic Labs secured a $2.1 billion Series B financing in May.

Sources indicated to TechCrunch that Wang's new venture may focus on building AI models designed to discover new applications for existing medications, potentially including drugs that previously failed clinical trials. Targeting FDA-approved drugs for repositioning can offer a significantly faster path to revenue compared to de novo drug development, given that these compounds have already cleared baseline safety evaluations.

The aggressive capital deployment into AI-driven drug discovery reflects a broader venture capital willingness to back technical founders tackling capital-intensive industries. Wang's background as a young founder who dropped out of Harvard to join OpenAI also highlights a resurgent venture capital comfort with backing collegiate dropouts who possess specialized technical expertise in foundational AI research.

Sources

  1. 01 OpenAI researcher Miles Wang in talks to launch AI drug discovery startup valued at $2B — TechCrunch